GLG Partners’s Fate Therapeutics FATE Stock Holding History

GLG Partners’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-20,754	Closed	-$94K	–	364
2017 Q1	$94K	Buy	+20,754	New	+$75.9K	﹤0.01%	422

Other funds holding FATE

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GLG Partners's FATE Position: Q2 2017 in Review

GLG Partners sold out of Fate Therapeutics (FATE) in Q2 2017, closing a stake of 20,754 shares — an estimated $94K sold.

GLG Partners first reported a position in FATE in Q1 2017 and held it in 1 quarter. The position peaked at $94K in Q1 2017. 60 funds tracked by Wall St. Rank hold FATE as of Q2 2017.

GLG Partners reported no remaining Fate Therapeutics position as of Q2 2017 after selling out during the quarter.
GLG Partners sold 20,754 Fate Therapeutics shares in Q2 2017, an estimated $94K.
GLG Partners first reported a position in Fate Therapeutics in Q1 2017 and held it in 1 quarter.
GLG Partners's Fate Therapeutics position peaked at $94K in Q1 2017.
60 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.